Straits Times Index
3,293.13 +20.41 (+0.62%) S&P 500
5,071.63 +1.08 (+0.02%) Dow
38,460.92 -42.77 (-0.11%) Nasdaq
15,712.75 +16.11 (+0.10%) Bitcoin USD
64,575.02 -2,156.46 (-3.23%) CMC Crypto 200
1,395.30 -28.80 (-2.02%)
Genscript Biotech Corporation (GNNSF)
| Previous close | 1.5000 |
| Open | 1.5000 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 1.5000 - 1.5000 |
| 52-week range | 1.5000 - 3.2000 |
| Volume | |
| Avg. volume | 824 |
| Market cap | 3.186B |
| Beta (5Y monthly) | 1.03 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.0500 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | 05 Jun 2017 |
| 1y target est | N/A |
PR NewswireGenScript Biotech Releases 2023 ESG Report: Deepening Green Development Practices, Constructing Sustainable Future Blueprint
Recently, GenScript Biotech Corporation (HK.1548), a world leader in technologies and services for life science R&D and manufacture, released its 2023 Environmental, Social, and Governance (ESG) report. This report showcases the company's dedicated efforts in ESG governance, corporate social responsibility fulfillment, and environmental conservation practices. It underscores GenScript's unwavering commitment to advancing green initiatives and seamlessly integrating sustainable development strate
PR NewswireGenScript Singapore's Open Day Reveals Pioneering AI Capabilities in Recombinant Protein Production and Drug Discovery
GenScript, a global leader in life sciences and biotechnology, successfully hosted an Open Day event at its Singapore facility on the 16th of April, welcoming more than 50 representatives from Singapore. This event provided an exclusive look into GenScript's state-of-the-art gene and protein production facility, particularly highlighting the company's advancements in AI-driven gene and recombinant protein production. Guests embarked on a guided tour through the facility, witnessing the precision
PR NewswireMultiply Labs and GenScript Biotech Corporation Collaborate to Automate the Cell Isolation and Enrichment Phase of Cell Therapy Manufacturing
GenScript Biotech Corporation (GenScript), one of the world's leading providers of life-science research tools and services, and Multiply Labs, a robotics company developing industry-leading automated manufacturing systems to produce individualized drugs, today announced a strategic partnership around the automation of the cell isolation phase of cell therapy manufacturing, reducing the complexity of this laborious process.
